Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 2, 2011, Pages 285-292

  Xu, Baixuan ^a   Guan, Zhiwei ^a   Liu, Changbin ^a   Wang, Ruimin ^a   Yin, Dayi ^a   Zhang, Jinming ^a   Chen, Yingmao ^a   Yao, Shulin ^a   Shao, Mingzhe ^a   Wang, Hui ^a   Tian, Jiahe ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

18F Fluorodeoxythymidine; 18F Fluorodeoxyglucose; Clinical decision making; Multimodality imaging; Pulmonary lesions

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOTOXIC AGENT; FLUORODEOXYGLUCOSE F 18; FLUORODEOXYTHYMIDINE F 18; TRACER; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG GRANULOMA; LUNG LESION; LUNG NODULE; LUNG PSEUDOTUMOR; LUNG SCINTISCANNING; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PHYSICIAN; PNEUMONIA; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TUBERCULOSIS; COMPUTER ASSISTED TOMOGRAPHY; LUNG DISEASE; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 79551566632     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1625-8     Document Type: Article

References (25)

1. Newsline 2008 Molecular imaging in the spotlight at RSNA 2007 J Nucl Med 49 1 19N
2. JG Rajendran DA Mankoff 2007 Beyond detection: novel applications for PET imaging to guide cancer therapy J Nucl Med 48 6 855 856 10.2967/jnumed.107. 039768 17536105 (Pubitemid 46909910)
3. A van Waarde DC Cobben AJ Suurmeijer B Maas W Vaalburg EF de Vries, et al. 2004 Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model J Nucl Med 45 4 695 700 15073267
4. CL Ho SR Chen DWC Yeung TK Cheng 2007 Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma J Nucl Med 48 902 909 1:CAS:528:DC%2BD2sXhtVert7bF 10.2967/jnumed.106.036673 17504862 (Pubitemid 46909918)
5. D Rischin RJ Hicks R Fisher D Binns J Corry S Porceddu, et al. 2006 Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2098 2104 10.1200/JCO.2005.05.2878 16648512 (Pubitemid 46622121)
6. HM Linden SA Stekhova JM Link JR Gralow RB Livingston GK Ellis, et al. 2006 Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer J Clin Oncol 24 2793 2799 1:CAS:528:DC%2BD28XntV2hu7c%3D 10.1200/JCO.2005.04.3810 16682724 (Pubitemid 46630578)
7. JH Tian XF Yang LJ Yu P Chen J Xin L Ma, et al. 2008 A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG J Nucl Med 49 2 186 194 10.2967/jnumed.107.044966 18199618 (Pubitemid 351225655)
8. T Bunyaviroch RE Coleman 2006 PET evaluation of lung cancer J Nucl Med 47 3 451 469 16513615
9. LG Strauss 1996 Fluoro-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients Eur J Nucl Med 23 1409 1415 1:STN:280:DyaK28zns1GhtA%3D%3D 10.1007/BF01367602 8781149 (Pubitemid 26340597)
10. H Schöder HWD Yeung SM Larson 2005 CT in PET/CT: essential features of interpretation J Nucl Med 46 1249 1251 16085577
11. SK Kim M Allen-Auerbach J Goldin BJ Fueger M Dahlbom M Brown, et al. 2007 Accuracy of PET/CT in characterization of solitary pulmonary lesions J Nucl Med 48 214 220 17268017
12. R Beck B Röper JM Carlsen M Huisman J Lebschi N Andratschke, et al. 2007 Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine J Nucl Med 48 973 980 1:CAS:528: DC%2BD2sXhtVert7fJ 10.2967/jnumed.106.038570 17536108 (Pubitemid 46909926)
13. AR Hsu W Cai A Veeravagu KA Mohamedali K Chen S Kim, et al. 2007 Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel J Nucl Med 48 445 454 1:CAS:528:DC%2BD2sXhtVertLzF 17332623
14. HN Wagnar 2006 From molecular imaging to molecular medicine J Nucl Med 47 7 13N 39N
15. H Vesselle J Grierson M Muzi JM Pugsley RA Schmidt P Rabinowitz, et al. 2002 In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors Clin Cancer Res 8 11 3315 3323 1:CAS:528:DC%2BD38XpsVCgtr0%3D 12429617
16. JR Grierson AF Shields 2000 Radiosynthesis of 3′-deoxy-3′- [(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo Nucl Med Biol 27 2 143 156 1:CAS:528:DC%2BD3cXisFGqtbg%3D 10.1016/S0969- 8051(99)00104-3 10773543 (Pubitemid 30204569)
17. SN Reske S Deisenhofer 2006 Is 3′-deoxy-3′-(18)F- fluorothymidine a better marker for tumour response than (18)F- fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 33 Suppl 1 38 43 10.1007/s00259-006-0134-2 16721567
18. HA Wieder H Geinitz R Rosenberg F Lordick K Becker A Stahl, et al. 2007 PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer Eur J Nucl Med Mol Imaging 34 6 878 883 1:CAS:528:DC%2BD2sXltl2htL4%3D 10.1007/s00259-006-0292- 2 17195074 (Pubitemid 46798949)
19. AK Buck G Halter H Schirrmeister J Kotzerke I Wurziger G Glatting, et al. 2003 Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG J Nucl Med 44 9 1426 1431 1:CAS:528:DC%2BD3sXnvVSrtrc%3D 12960187
20. CS Yap J Czernin MC Fishbein RB Cameron C Schiepers ME Phelps, et al. 2006 Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography Chest 129 393 401 10.1378/chest.129.2.393 16478857 (Pubitemid 43289860)
21. Y Yamamoto Y Nishiyama S Ishikawa J Nakano SS Chang S Bandoh, et al. 2007 Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer Eur J Nucl Med Mol Imaging 34 10 1610 1616 1:CAS:528:DC%2BD2sXhtVOit7bF 10.1007/s00259-007-0449-7 17530250 (Pubitemid 47476919)
22. EGC Troost WV Vogel MAW Merkx PJ Slootweg HAM Marres WJM Peeters, et al. 2007 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients J Nucl Med 48 5 726 735 10.2967/jnumed.106.037473 17475960 (Pubitemid 47604972)
23. G Porenta 2007 Being right for the right reason: better than just being right? J Nucl Med 48 3 335 336 17332608
24. BE Hillner BA Siegel D Liu AF Shields IF Gareen L Hanna, et al. 2008 Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry J Clin Oncol 26 13 2155 2161 10.1200/JCO.2007.14.5631 18362365
25. H Vesselle J Grierson LM Peterson M Muzi DA Mankoff KA Krohn 2003 18F-Fluorothymidine radiation dosimetry in human PET imaging studies J Nucl Med 44 9 1482 1488 1:CAS:528:DC%2BD3sXnvVSrt7s%3D 12960196